Stockscreener 앱 받기
23.57
1.99%
0.46
시간 외 거래:
23.99
0.42
+1.78%
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 - marketscreener.com
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Denali Therapeutics Inc. Revenue Breakdown – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
DNLI Maintained by Morgan Stanley -- Price Target Raised to $36 - GuruFocus
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36 - Moomoo
DNLI|Denali Therapeutics Inc|Price:23.110|Chg%:-0.310 - TradingKey
Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey? - Yahoo Finance
Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline - Ad-hoc-news.de
Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval? - Yahoo Finance
Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return - Sahm
Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily
Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35 - Moomoo
DENALI THERAPEUTICS INC. : DEUTSCHE BANK RAISES TARGET PRICE TO $35 FROM $31 - Bitget
Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC) - The Globe and Mail
Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating - marketscreener.com
Will Recent Setbacks Impact Growth Prospects of DNLI Stock? - Yahoo Finance
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $31 - Moomoo
Jefferies Keeps Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail
Denali Therapeutics (DNLI) Faces 12.4% Decline in Share Value - GuruFocus
Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan - Moomoo
Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating - Moomoo
Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg - GuruFocus
JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating By Investing.com - Investing.com Nigeria
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Stocktwits
JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating - Investing.com
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? -- Barrons.com - Moomoo
Denali Therapeutics (DNLI) Investor Day 2025 Summary - Quartr
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI) - Sahm
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier - The Manila Times
Denali CEO to keynote AAIC 2026, highlighting a... - Pluang
Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s - Stock Titan
Denali Therapeutics stock hits 52-week high at $26.95 By Investing.com - Investing.com South Africa
Denali Therapeutics stock hits 52-week high at $26.95 - Investing.com
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - Yahoo Finance
T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A - Stock Titan
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
DNLIDenali Therapeutics Inc Volatility & Greeks - Finviz
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - Sahm
Denali Therapeutics stock stays focused on pipeline progress. - ad-hoc-news.de
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com
Denali to sell priority review voucher for $195M cash boost - MSN
Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh - TradingView
Price to earnings forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to book forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI) - TradingView
Enterprise value to EBITDA forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
1.97%
0.83%
자본화:
|
볼륨(24시간):